Biotechnology Value Fund L P's Form 4 filing
XOMA Royalty Corp (XOMA) · filed Jan 28, 2025
- Accession no.
- 0000921895-25-000177
- Filed
- Jan 28, 2025, 5:23 PM ET
- Trade date
- Jan 24, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $17.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | 10% Owner |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | 10% Owner |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | 10% Owner |
| BVF II GP LLCCIK 0001803806 | 10% Owner |
| BVF GP Holdings LLCCIK 0001803809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 24, 2025 | Common Stock, $0.0075 par value per share | SSaleDisposed | −339,679 | $26.10 | −$8,865,621.9 | 1,450,165 | Direct | |
| Jan 24, 2025 | Common Stock, $0.0075 par value per share | SSaleDisposed | −85,776 | $26.10 | −$2,238,753.6 | 1,532,861 | Direct | |
| Jan 24, 2025 | Common Stock, $0.0075 par value per share | SSaleDisposed | −75,287 | $26.10 | −$1,964,990.7 | 0 | Direct | |
| Jan 24, 2025 | Common Stock, $0.0075 par value per share | SSaleDisposed | −149,975 | $26.10 | −$3,914,347.5 | 0 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.